Probi AB
STO:PROB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
188.7892
351
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Probi AB
Probi AB
Long-Term Debt
Probi AB
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Probi AB
STO:PROB
|
Long-Term Debt
kr68.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Long-Term Debt
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Long-Term Debt
kr8.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Long-Term Debt
kr1.9B
|
CAGR 3-Years
230%
|
CAGR 5-Years
97%
|
CAGR 10-Years
67%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Long-Term Debt
kr11.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
31%
|
|
|
BioArctic AB
STO:BIOA B
|
Long-Term Debt
kr2.2m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Probi AB
Glance View
Probi AB engages in the development and sale of probiotics. The company is headquartered in Lund, Skane and currently employs 175 full-time employees. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The firm's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The firm is a parent of Probi Food AB and Probi Feed AB.
See Also
What is Probi AB's Long-Term Debt?
Long-Term Debt
68.2m
SEK
Based on the financial report for Jun 30, 2024, Probi AB's Long-Term Debt amounts to 68.2m SEK.
What is Probi AB's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
14%
Over the last year, the Long-Term Debt growth was 43%. The average annual Long-Term Debt growth rates for Probi AB have been 14% over the past three years .
You don't have any saved screeners yet
